Cymetra

A treatment option for refractory ulcers

Daniel Levy, Meggan R. Banta, Carlos A. Charles, William H. Eaglstein, Robert Kirsner

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Cymetra™ is a micronized, injectable form of AlloDerm® (LifeCell Corporation, Branchberg, New Jersey), an allogeneic dermal matrix product developed as a filler substance for cosmetic use. Recently, Cymetra has been reported to be effective in the healing of recalcitrant sinus tracts in two patients. Objective: The objective of the authors' study was to evaluate the safety and efficacy of Cymetra as an adjuvant in the treatment of a variety of chronic wounds. Methods: A retrospective chart review was performed for patients who were treated with Cymetra at the CURE Wound Care Center at the University of Miami, Miami, Florida. Results: Patients with various types of chronic ulcers, including pyoderma gangrenosum, eosinophilic fasciitis, chronic pressure ulcers, post-operative ulcers, venous insufficiency ulcers, and livedo vasculitis, were treated with Cymetra injections. All patients had refractory disease and failed to respond to prior treatments, which included Apligraf® (Organogenesis, Canton, Massachusetts), Dermagraft (Smith & Nephew, Largo, Florida), V.A.C.® Therapy™ (KCI Inc., San Antonio, Texas), compression, etanercept, mycophenolate mofetil, prednisone, infliximab, cyclosporine, antibiotics, debridement, intralesional triamcinolone acetonide, and granulocyte/macrophage colony-stimulating factor (GMCSF). Of the 13 patients treated with Cymetra, nine patients' ulcers (69%) healed completely. Conclusions: Cymetra was well tolerated, and the majority of patients achieved complete healing of their ulcers after treatment.

Original languageEnglish
Pages (from-to)359-363
Number of pages5
JournalWounds
Volume16
Issue number12
StatePublished - Dec 1 2004

Fingerprint

Ulcer
Therapeutics
Mycophenolic Acid
Pyoderma Gangrenosum
Varicose Ulcer
Triamcinolone Acetonide
Venous Insufficiency
Injections
Organogenesis
Pressure Ulcer
Wounds and Injuries
Debridement
Granulocyte-Macrophage Colony-Stimulating Factor
Vasculitis
Prednisone
Cymetra
Cosmetics
Cyclosporine
Anti-Bacterial Agents
Safety

ASJC Scopus subject areas

  • Surgery

Cite this

Levy, D., Banta, M. R., Charles, C. A., Eaglstein, W. H., & Kirsner, R. (2004). Cymetra: A treatment option for refractory ulcers. Wounds, 16(12), 359-363.

Cymetra : A treatment option for refractory ulcers. / Levy, Daniel; Banta, Meggan R.; Charles, Carlos A.; Eaglstein, William H.; Kirsner, Robert.

In: Wounds, Vol. 16, No. 12, 01.12.2004, p. 359-363.

Research output: Contribution to journalArticle

Levy, D, Banta, MR, Charles, CA, Eaglstein, WH & Kirsner, R 2004, 'Cymetra: A treatment option for refractory ulcers', Wounds, vol. 16, no. 12, pp. 359-363.
Levy D, Banta MR, Charles CA, Eaglstein WH, Kirsner R. Cymetra: A treatment option for refractory ulcers. Wounds. 2004 Dec 1;16(12):359-363.
Levy, Daniel ; Banta, Meggan R. ; Charles, Carlos A. ; Eaglstein, William H. ; Kirsner, Robert. / Cymetra : A treatment option for refractory ulcers. In: Wounds. 2004 ; Vol. 16, No. 12. pp. 359-363.
@article{352b1258a70e4577abe44b3cd255e9d8,
title = "Cymetra: A treatment option for refractory ulcers",
abstract = "Background: Cymetra™ is a micronized, injectable form of AlloDerm{\circledR} (LifeCell Corporation, Branchberg, New Jersey), an allogeneic dermal matrix product developed as a filler substance for cosmetic use. Recently, Cymetra has been reported to be effective in the healing of recalcitrant sinus tracts in two patients. Objective: The objective of the authors' study was to evaluate the safety and efficacy of Cymetra as an adjuvant in the treatment of a variety of chronic wounds. Methods: A retrospective chart review was performed for patients who were treated with Cymetra at the CURE Wound Care Center at the University of Miami, Miami, Florida. Results: Patients with various types of chronic ulcers, including pyoderma gangrenosum, eosinophilic fasciitis, chronic pressure ulcers, post-operative ulcers, venous insufficiency ulcers, and livedo vasculitis, were treated with Cymetra injections. All patients had refractory disease and failed to respond to prior treatments, which included Apligraf{\circledR} (Organogenesis, Canton, Massachusetts), Dermagraft (Smith & Nephew, Largo, Florida), V.A.C.{\circledR} Therapy™ (KCI Inc., San Antonio, Texas), compression, etanercept, mycophenolate mofetil, prednisone, infliximab, cyclosporine, antibiotics, debridement, intralesional triamcinolone acetonide, and granulocyte/macrophage colony-stimulating factor (GMCSF). Of the 13 patients treated with Cymetra, nine patients' ulcers (69{\%}) healed completely. Conclusions: Cymetra was well tolerated, and the majority of patients achieved complete healing of their ulcers after treatment.",
author = "Daniel Levy and Banta, {Meggan R.} and Charles, {Carlos A.} and Eaglstein, {William H.} and Robert Kirsner",
year = "2004",
month = "12",
day = "1",
language = "English",
volume = "16",
pages = "359--363",
journal = "Wounds",
issn = "1044-7946",
publisher = "HMP Communications",
number = "12",

}

TY - JOUR

T1 - Cymetra

T2 - A treatment option for refractory ulcers

AU - Levy, Daniel

AU - Banta, Meggan R.

AU - Charles, Carlos A.

AU - Eaglstein, William H.

AU - Kirsner, Robert

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Background: Cymetra™ is a micronized, injectable form of AlloDerm® (LifeCell Corporation, Branchberg, New Jersey), an allogeneic dermal matrix product developed as a filler substance for cosmetic use. Recently, Cymetra has been reported to be effective in the healing of recalcitrant sinus tracts in two patients. Objective: The objective of the authors' study was to evaluate the safety and efficacy of Cymetra as an adjuvant in the treatment of a variety of chronic wounds. Methods: A retrospective chart review was performed for patients who were treated with Cymetra at the CURE Wound Care Center at the University of Miami, Miami, Florida. Results: Patients with various types of chronic ulcers, including pyoderma gangrenosum, eosinophilic fasciitis, chronic pressure ulcers, post-operative ulcers, venous insufficiency ulcers, and livedo vasculitis, were treated with Cymetra injections. All patients had refractory disease and failed to respond to prior treatments, which included Apligraf® (Organogenesis, Canton, Massachusetts), Dermagraft (Smith & Nephew, Largo, Florida), V.A.C.® Therapy™ (KCI Inc., San Antonio, Texas), compression, etanercept, mycophenolate mofetil, prednisone, infliximab, cyclosporine, antibiotics, debridement, intralesional triamcinolone acetonide, and granulocyte/macrophage colony-stimulating factor (GMCSF). Of the 13 patients treated with Cymetra, nine patients' ulcers (69%) healed completely. Conclusions: Cymetra was well tolerated, and the majority of patients achieved complete healing of their ulcers after treatment.

AB - Background: Cymetra™ is a micronized, injectable form of AlloDerm® (LifeCell Corporation, Branchberg, New Jersey), an allogeneic dermal matrix product developed as a filler substance for cosmetic use. Recently, Cymetra has been reported to be effective in the healing of recalcitrant sinus tracts in two patients. Objective: The objective of the authors' study was to evaluate the safety and efficacy of Cymetra as an adjuvant in the treatment of a variety of chronic wounds. Methods: A retrospective chart review was performed for patients who were treated with Cymetra at the CURE Wound Care Center at the University of Miami, Miami, Florida. Results: Patients with various types of chronic ulcers, including pyoderma gangrenosum, eosinophilic fasciitis, chronic pressure ulcers, post-operative ulcers, venous insufficiency ulcers, and livedo vasculitis, were treated with Cymetra injections. All patients had refractory disease and failed to respond to prior treatments, which included Apligraf® (Organogenesis, Canton, Massachusetts), Dermagraft (Smith & Nephew, Largo, Florida), V.A.C.® Therapy™ (KCI Inc., San Antonio, Texas), compression, etanercept, mycophenolate mofetil, prednisone, infliximab, cyclosporine, antibiotics, debridement, intralesional triamcinolone acetonide, and granulocyte/macrophage colony-stimulating factor (GMCSF). Of the 13 patients treated with Cymetra, nine patients' ulcers (69%) healed completely. Conclusions: Cymetra was well tolerated, and the majority of patients achieved complete healing of their ulcers after treatment.

UR - http://www.scopus.com/inward/record.url?scp=12444318572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444318572&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 359

EP - 363

JO - Wounds

JF - Wounds

SN - 1044-7946

IS - 12

ER -